Kancera AB (publ) today reports that the Finnish regulatory agency (FIMEA) has approved Kancera’s application to conduct a phase I study of KAND145, the company’s second generation fractalkine blocking candidate drug.
Read MoreKancera AB (publ) today announces that the top line results from the FRACTAL study are delayed. The company expects that results will be presented by the end of December 2023.
Read MoreKancera AB (publ) announces that Dr. Markus Jerling has been appointed as new Chief Medical Officer, effective from September 1, 2023.
Read MoreIn connection with the release of the financial interim report for the second quarter of 2023, Kancera AB (publ) provides an operational update and announces that top line results from the ongoing FRACTAL study are expected to be presented...
Read MoreThe period in brief – financial summary for the second quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 16.5 million (SEK 14.7 million). Operating income for the second quarter amounted to SEK...
Read MoreKancera AB (publ) today comments on the potential for its fractalkine blocking drug candidate KAND567 based on a newly published research publication that summarizes clinical research addressing the pathology driving role of fractalkine axis in cardiovascular disease. KAND567 is...
Read MoreKancera AB (publ) today reports that the first patient in the KANDOVA study, a combined phase Ib/IIa study in ovarian cancer, has been dosed with KAND567.
Read MoreKancera AB (publ) today announces that Peter Selin is appointed as new Chief Executive Officer (CEO) as of July 1 2023. At the same time, Thomas Olin is appointed as Executive Vice President and Chief Scientific Officer (CSO).
Read MoreThe period in briefJanuary – MarchFinancial summary for the first quarter• Net sales amounted to SEK 0 million (SEK 0).• R&D expenses amounted to SEK 15,2 million (SEK10,6 million).• Operating profit for the first quarter amounted to SEK -17.2...
Read MoreKancera today reports that patient screening to the KANDOVA-study, a combined phase Ib/IIa study of the Fractalkine blocker KAND567 in ovarian cancer patients, has been started at the Karolinska University Hospital.
Read More